Fig. 1

BrainSync-AD study design

AD, Alzheimer’s disease; γ, gamma; tACS, transcranial alternating current stimulation; EEG, electroencephalography; TMS, transcranial magnetic stimulation; MRI, magnetic resonance imaging; PET, positron emission tomography; T00, baseline; T08, 8-week follow-up; T16, 16-week follow-up; T24, 24-week follow-up. Safety and feasibility will be constantly monitored throughout the duration of the study. Neuropsychological assessment, blood sampling, EEG, and TMS will be collected at T00, T08, T16, and T24. MRI and amyloid-PET will be collected at T00 and T08